Fundies. English
Aprea Therapeutics, Inc.
EDGAR42 filing records in this dataset, filed from 2019-09-06 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 41.2 million Unit_Standard_USD_3t11JB_1hkKOMIMiLv1vfg Source
Exact value
41200000 Unit_Standard_USD_3t11JB_1hkKOMIMiLv1vfg
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 12.4 million Unit_Standard_shares_vi-5l8I7FUucnJupBmjV2A Source
Exact value
12391136 Unit_Standard_shares_vi-5l8I7FUucnJupBmjV2A
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-12.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: Multiple units; comparison withheld· newest 2024-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2022-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 359,142Prior period
−Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.96 million
–
Current period
−Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.6 million
–
Exact inputs and evidence
-12599569 − -12958711 = 359142 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww
-12958711 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12599569 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 662,279Prior period
−Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 13.56 million
–
Current period
−Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.89 million
–
Exact inputs and evidence
-12894439 − -13556718 = 662279 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww
-13556718 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12894439 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.96 million Exact valueExact value: -12958711 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 2024-01-01 – 2024-12-31: -12958711 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 13.56 million Exact valueExact value: -13556718 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 2024-01-01 – 2024-12-31: -13556718 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.6 million Exact valueExact value: -12599569 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 2025-01-01 – 2025-12-31: -12599569 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 12.89 million Exact valueExact value: -12894439 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww 2025-01-01 – 2025-12-31: -12894439 Unit_Standard_USD_LZWdiRJgp0KgKepPqZxkww Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
42 filings · 2,606 latest values · 2,606 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001781983, 1781983, APRE, edgar:1781983
Also known as Aprea Therapeutics, Inc.